ClinicaliQ Trial Snapshot
- A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) — Recruiting • Phase III • Oncology • NCT05519085.
- What is being tested: A randomised comparison of two triple-drug regimens—mezigdomide (a novel cereblon modulator) combined with bortezomib and dexamethasone versus the established pomalidomide combination—in patients with relapsed or refractory multiple myeloma who have received 1-3 prior treatments.
- Patient eligibility overview: The trial recruits adults with documented relapsed or refractory multiple myeloma who have had between 1-3 prior treatment lines, indicating an intermediate-heavily pre-treated population with established disease resistance.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
Eligibility Snapshot
- - Participant has documented diagnosis of MM and measurable disease, defined as any of the following:. i) M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or. ii) M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP). iii) For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio. * Participants received 1 to 3 prior lines of antimyeloma therapy. * Participants achieved minimal response [MR] or better to at least 1 prior antimyeloma therapy.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.